EcoDrugPlus

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSELUG00000003123
Gene Symbol: PSMA3
3 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSELUG00000011933
Gene Symbol: PSMA5
2 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSELUG00000005656
Gene Symbol: PSMA6
4 Cross references
249 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSELUG00000018226
Gene Symbol: PSMA8
4 Cross references
165 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSELUG00000014893
Gene Symbol: PSMB1
2 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSELUG00000023751
Gene Symbol: PSMB2
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSELUG00000009149
Gene Symbol: PSMB3
1 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSELUG00000016945
Gene Symbol: PSMB4
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSELUG00000018917
Gene Symbol: PSMB6
2 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSELUG00000019284
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSELUG00000023299
Gene Symbol: PSMB8A
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSELUG00000011072
Gene Symbol: PSMD4B
1 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).